JP2021533197A5 - - Google Patents
Info
- Publication number
- JP2021533197A5 JP2021533197A5 JP2021529257A JP2021529257A JP2021533197A5 JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5 JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex
- transferrin receptor
- complex according
- receptor antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006544A JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713959P | 2018-08-02 | 2018-08-02 | |
| US62/713,959 | 2018-08-02 | ||
| PCT/US2019/044960 WO2020028841A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating pompe disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Division JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533197A JP2021533197A (ja) | 2021-12-02 |
| JP2021533197A5 true JP2021533197A5 (enExample) | 2022-08-10 |
Family
ID=69230844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529257A Pending JP2021533197A (ja) | 2018-08-02 | 2019-08-02 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210317226A1 (enExample) |
| EP (1) | EP3830127A4 (enExample) |
| JP (2) | JP2021533197A (enExample) |
| KR (1) | KR20210054513A (enExample) |
| CN (2) | CN118662653A (enExample) |
| CA (1) | CA3108285A1 (enExample) |
| EA (1) | EA202190417A1 (enExample) |
| IL (1) | IL280483A (enExample) |
| WO (1) | WO2020028841A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021226107A1 (en) * | 2020-05-05 | 2021-11-11 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20250058123A (ko) * | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1620564A4 (en) * | 2003-04-18 | 2008-03-12 | Cytovia Inc | METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS |
| EP3795687A1 (en) * | 2014-05-23 | 2021-03-24 | Genzyme Corporation | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
| DK3386534T3 (da) * | 2015-12-08 | 2020-11-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| WO2017184529A1 (en) * | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
-
2019
- 2019-08-02 US US17/265,016 patent/US20210317226A1/en not_active Abandoned
- 2019-08-02 CA CA3108285A patent/CA3108285A1/en active Pending
- 2019-08-02 KR KR1020217005994A patent/KR20210054513A/ko active Pending
- 2019-08-02 EP EP19844183.4A patent/EP3830127A4/en active Pending
- 2019-08-02 EA EA202190417A patent/EA202190417A1/ru unknown
- 2019-08-02 WO PCT/US2019/044960 patent/WO2020028841A1/en not_active Ceased
- 2019-08-02 CN CN202410663435.8A patent/CN118662653A/zh active Pending
- 2019-08-02 JP JP2021529257A patent/JP2021533197A/ja active Pending
- 2019-08-02 CN CN201980064590.5A patent/CN112912399A/zh active Pending
-
2021
- 2021-01-28 IL IL280483A patent/IL280483A/en unknown
-
2025
- 2025-01-17 JP JP2025006544A patent/JP2025071093A/ja active Pending